Wednesday, 27 August 2014

Pharmaceutical industry code of conduct fails to find favour

Adjunct Associate Professor Ken Harvey, School of Public Health and Preventive Medicine, comments on how the pharmaceutical industry code of conduct fails to find favour in The Conversation.

The Australian Competition and Consumer Commission (ACCC) is considering whether to approve the latest Medicines Australia code of conduct for pharmaceutical companies.

The code lays out disclosure requirements for payments and other transfers of value (payment for sitting on drug company advisory boards; air-fares, accommodation and conference registration fees; funds for drug company-sponsored lectures). Doctors are influenced by such payments so it’s important that the public (and their colleagues) know the extent of the largesse.

No comments:

Post a Comment

linkwithin

Related Posts Plugin for WordPress, Blogger...